{
    "clinical_study": {
        "@rank": "120982", 
        "arm_group": [
            {
                "arm_group_label": "Regenexx PL-Disc", 
                "arm_group_type": "Active Comparator", 
                "description": "Injection of Regenexx PL-Disc into the epidural space once a week for two weeks."
            }, 
            {
                "arm_group_label": "Steroid Epidural", 
                "arm_group_type": "Active Comparator", 
                "description": "Injection of steroid into the epidural space once a week for two weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare the improvement in subject-reported\n      clinical outcomes for Regenexx PL-Disc vs. steroid epidural for treatment of lumbar\n      radiculopathy, from baseline to 3 months, with continued evaluation of efficacy and\n      durability up to 12 months.\n\n      Secondary objectives include incidence of post-operative complications, adverse events,\n      re-injections, and surgical intervention; change in pain score and use of pain medications."
        }, 
        "brief_title": "Regenexx\u2122 PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Radiculopathy", 
            "Herniated Disc", 
            "Disc Degeneration"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Intervertebral Disk Degeneration", 
                "Intervertebral Disk Displacement", 
                "Radiculopathy"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prospective, single-blinded, randomized, controlled to include 25 subjects treated with\n      Regenexx PL-Disc and 25 subjects treated with steroid epidural injection with the steroid\n      epidural group crossing over to the PL-Disc injection group at 3 months.\n\n      Subjects will have symptoms consistent with lumbar radiculopathy confirmed by physical\n      examination.\n\n      Subjects will be enrolled within 60 days prior to injection and take part in follow-up\n      visits for one year following treatment.  A preoperative visit will occur at the time of\n      enrollment; follow-up visits will occur at the clinical site at 6 weeks, 3 months, 6 months\n      and 12 months post injection. Subjects will remain blinded to the treatment allocation\n      through at least the 3 month primary endpoint. Control subjects not improving after the 3\n      month visit will be unblinded and given the opportunity to cross-over to the PL-Disc group.\n\n      Subjects will complete the study following the 1 year follow-up visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pain, spasm, or functional disability in the low back and diagnosed as radiculopathy\n             having failed conservative treatment (e.g. NSAIDs, physician initiated physical\n             therapy) for at least 3 months and not longer than 2 years\n\n          -  Significant functional disability related to pain, lack of strength, or other back or\n             leg symptoms\n\n          -  Physical examination consistent with lumbar radiculopathy\n\n          -  Lumbar disc bulge, herniation, and/or Kader grade 2 or greater multifidus atrophy\n             evident on MRI and consistent with physical exam findings\n\n          -  Is independent, ambulatory, and can comply with all post-operative evaluations and\n             visits\n\n        Exclusion Criteria:\n\n          -  Symptomatic central or foraminal stenosis\n\n          -  Previous low back surgery\n\n          -  Prior epidural steroid injection or other low back injection therapy within the past\n             year\n\n          -  >50% loss of disc height at the symptomatic level\n\n          -  Spondylolisthesis\n\n          -  Inflammatory or auto-immune based pathology (e.g., rheumatoid arthritis, systemic\n             lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)\n\n          -  Quinolone or Statin induced myopathy/tendinopathy\n\n          -  Severe neurogenic inflammation of the cutaneous nerves\n\n          -  Condition represents a worker's compensation case\n\n          -  Currently involved in a health-related litigation procedure\n\n          -  Is pregnant\n\n          -  Bleeding disorders\n\n          -  Currently taking anticoagulant or immunosuppressive medication\n\n          -  Allergy or intolerance to study medication\n\n          -  Use of chronic opioid,\n\n          -  Documented history of drug abuse within six months of treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850771", 
            "org_study_id": "RSI2013-RCT02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Regenexx PL-Disc", 
                "description": "Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.", 
                "intervention_name": "Regenexx PL-Disc", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Steroid Epidural", 
                "description": "Injection into the epidural space under image guidance of 3 mg of betamethasone.", 
                "intervention_name": "Steroid Epidural", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lumbar Radiculopathy", 
            "Disc bulge", 
            "Disc herniation", 
            "Disc degeneration"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Broomfield", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80021"
                }, 
                "name": "Centeno-Schultz Clinic"
            }, 
            "investigator": [
                {
                    "last_name": "Christopher Centeno, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ron Hanson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Schultz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ben Newton, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Blinded, Randomized Controlled Trial of Regenexx\u2122 PL-Disc Versus Steroid Epidurals for Treatment of Lumbar Radiculopathy", 
        "overall_contact": {
            "email": "studycandidate@regenexx.com", 
            "last_name": "Regenexx Information", 
            "phone": "1-888-525-3005"
        }, 
        "overall_official": {
            "affiliation": "Centeno-Schultz Clinic", 
            "last_name": "Christopher Centeno, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint for this study is the difference between treatment groups in the within patient mean change from baseline to 3 months in Oswestry Disability Index (ODI) scores.", 
            "measure": "Oswestry Disability Index Change from Baseline", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850771"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference between treatment groups in mean Functional Rating Index (FRI) scores at each follow-up timepoint.", 
                "measure": "Mean Functional Rating Index Scores", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 3 months, 6 months, 12 months"
            }, 
            {
                "description": "Difference between treatment groups in mean ODI scores at each follow-up timepoint", 
                "measure": "Mean ODI scores", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 3 months, 6 months, 12 months"
            }, 
            {
                "description": "Difference between treatment groups in mean 0-10 pain scales at each follow-up timepoint", 
                "measure": "Mean Pain Scales", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 3 months, 6 months, 12 months"
            }, 
            {
                "description": "Incidence of post-operative complications and adverse events between treatment groups.", 
                "measure": "Incidence of Complications and Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Incidence of re-injection and surgical operation between treatment groups.", 
                "measure": "Incidence of re-injection/re-operation", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Difference between treatment groups in use of pain medications at each follow-up timepoint", 
                "measure": "Use of pain medications", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 3 months, 6 months, 12 months"
            }, 
            {
                "description": "Time to resolution of post-operative complications and adverse events between treatment groups.", 
                "measure": "Time to Resolution of Complications and Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Time to re-injection and surgical operation between treatment groups.", 
                "measure": "Time to re-injection/re-operation", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Regenerative Sciences, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regenerative Sciences, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}